9 companies went public this week, raising $2 billion in the IPO market as year-to-date issuance surpassed 250 IPOs, almost 25% more than at this point last year. 3 large PE-backed deals, including two LBOs, each traded up over 10% and represented 79% of...read more
FibroGen, a biotech backed by Astellas and AstraZenec developing therapies for anemia and fibrosis, raised $146 million by offering 8.1 million shares at $18, toward the top of the $16 to $19 range. FibroGen plans to list on the NASDAQ under the symbol...read more
10 deals are on the IPO calendar to raise $2.2 billion for the week of November 10, 2014. The two largest, auto paint maker Axalta Coating Systems and contract...read more
FibroGen, which is developing treatments for anemia and fibrosis using a protein inhibitor platform, announced terms for its IPO on Thursday. The San Francisco, CA-based company plans to raise $124 million by offering 7.1 million shares at a price range of $16...read more
US IPO Weekly Recap: Virgin America flies high as IPO market reaches 250 with 9 new offerings
9 companies went public this week, raising $2 billion in the IPO market as year-to-date issuance surpassed 250 IPOs, almost 25% more than at this point last year. 3 large PE-backed deals, including two LBOs, each traded up over 10% and represented 79% of...read more
Feeling anemic? Biotech FibroGen prices IPO at $18, toward the top of the range
FibroGen, a biotech backed by Astellas and AstraZenec developing therapies for anemia and fibrosis, raised $146 million by offering 8.1 million shares at $18, toward the top of the $16 to $19 range. FibroGen plans to list on the NASDAQ under the symbol...read more
Week ahead: 10 US IPOs planned for the week of Nov 10 as IPO market hits 250 with Virgin America
10 deals are on the IPO calendar to raise $2.2 billion for the week of November 10, 2014. The two largest, auto paint maker Axalta Coating Systems and contract...read more
Billion dollar biotech: FibroGen sets terms for $124 million IPO
FibroGen, which is developing treatments for anemia and fibrosis using a protein inhibitor platform, announced terms for its IPO on Thursday. The San Francisco, CA-based company plans to raise $124 million by offering 7.1 million shares at a price range of $16...read more